Expression of vimentin filaments in canine malignant mammary gland tumors: A simulation of clinicopathological features of human breast cancer

Rismanchi, Sanaz; Yadegar, Orly; Muhammadnejad, Samad; Amanpour, Saeid; Taghizadeh-Jahed, Masoud; Muhammadnejad, Ahad

doi:10.3892/br.2014.312

Cited by 11 publications

(9 citation statements)

References 16 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A loss of epithelial markers (eg, e-cadherin, cytokeratin) and a gain of mesenchymal markers (eg, vimentin, fibronectin) is associated with epithelial-mesenchymal-transition, which is an important step in tumour progression and metastasis. [30][31][32][33] In malignant canine MT, a significant association between tumour size and advanced malignancy expressed by vimentin overexpression 34 and loss of e-cadherin expression could be demonstrated. 35 Based on this, the authors hypothesize there is not only a correlation between the size of the tumour and malignancy in general, but also a correlation between the degree of malignancy and size.…”

Section: Introductionmentioning

confidence: 93%

Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes

Gedon¹,

Wehrend

Failing

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

The purpose of this study was to evaluate a possible association between mammary tumour size and increasing degree of malignancy. Data of 625 dogs with a total of 1459 mammary tumours were analysed retrospectively. 80.3% dogs were intact, mean age at diagnosis was 9.7 ± 2.5 years, 75.8% were pure breed dogs. Median body weight was 20.0 kg. Malignant tumours (n = 580) were significantly larger than their benign counterparts (1.94 cm vs 0.90 cm in mean, respectively; P ≤ .0001), resulting in a positive correlation between increasing tumour size and a change from benign to malignant (P ≤ .0001; r s = 0.214). When malignant tumours were grouped into four degrees of increasing malignancy (complex/simple/solid/anaplastic carcinomas) a significant positive correlation between increasing tumour size and more malignant tumour degree (P ≤ .0001; r s = 0.195) could be demonstrated. In a number of cases, highly malignant tumours were found to arise within less malignant lesions, supporting the concept of a further progression within the malignant tumour subtypes. In patients with multiple tumours, mean tumour sizes for malignant tumours were significantly smaller compared to patients with only one tumour (1.67 vs 2.71 cm in mean, respectively; P < .0001). These findings suggest that mammary tumours progress not only from benign to malignant but also from low to highly malignant. An increase in diameter of only a few millimetres may therefore have a big impact on the patient's outcome.

show abstract

Section: Introductionmentioning

confidence: 93%

Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes

Gedon¹,

Wehrend

Failing

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…49 To our knowledge, such a relationship has not yet been demonstrated in canine gastric tumors, although vimentin expression in neoplastic epithelial cells has been associated with poor prognosis and shorter survival time in other types of neoplasms in the dog. 46,50 For decades, cancer studies were mainly focused on the characteristics of the neoplastic cells themselves. However, it is increasingly acknowledged that TAS contributes to cancer initiation, progression, and metastasis, and thus influences prognosis.…”

mentioning

confidence: 99%

Vimentin and Ki-67 immunolabeling in canine gastric carcinomas and their prognostic value

et al. 2022

View full text Add to dashboard Cite

This study evaluated the expression of vimentin and Ki-67 proliferative index (PI) by immunohistochemistry in 30 canine gastric carcinomas (GCs) and a possible association with clinical and pathological features and patient’s survival time. Vimentin immunoreactivity was assessed in neoplastic cells (in primary lesions, emboli, and metastases) and tumor-associated stroma (TAS) of canine GCs. Ki-67 PI was quantified in the neoplastic epithelial component. Vimentin immunolabeling in neoplastic cells was found in 30% of the primary lesions, in 82% of the neoplastic emboli, and in 50% of the metastases; in TAS, it was observed in all cases. A mean of 16% of the TAS was immunolabeled for vimentin. High vimentin immunolabeling in the TAS (>16%) was detected in 40% of cases. The average value of Ki-67 PI was 50%, and 80% of the lesions had Ki-67 PI above 20%. Vimentin immunolabeling in neoplastic cells was more frequent in less-differentiated carcinomas (diffuse [29%] and indeterminate types [75%]) than well-differentiated carcinomas (intestinal type [0%], P = .049). No significant differences were observed in vimentin immunolabeling in the TAS or Ki-67 PI according to histological diagnosis, depth of invasion, presence of neoplastic emboli or metastases. However, vimentin immunolabeling in the TAS was positively correlated with Ki-67 PI ( r = .394, P = .031). Furthermore, a moderate negative correlation was observed between Ki-67 PI and survival time ( r = −0.540). Our results suggest that vimentin and Ki-67 PI have potential for providing prognostic information in cases of canine GCs.

show abstract

“…34,35 Vimentin was scored as negative (0), weak (1), and strong (2). 36 For all markers, the highest score for the four spots from each tumor was used for further analysis.…”

Section: Scoringmentioning

confidence: 99%

Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus–Positive and Human Papillomavirus–Negative Oropharyngeal Squamous Cell Carcinoma

Mohamed

Haglund

Jouhi

et al. 2020

J Histochem Cytochem.

View full text Add to dashboard Cite

Oropharyngeal squamous cell carcinoma (OPSCC) is subclassified by the World Health Organization into two different entities: human papillomavirus (HPV)-positive and HPV-negative tumors. HPV infection promotes the epithelial-to-mesenchymal transition (EMT) and transformation of keratinocyte stem cells into cancer stem cells. EMT is a crucial process in the carcinogenesis of epithelial-derived malignancies, and we aimed to study the role of its markers in OPSCC. This study consists of 202 consecutive OPSCC patients diagnosed and treated with curative intent. We examined E-cadherin, β-catenin, and vimentin expression using immunohistochemistry and compared these with tumor and patient characteristics and treatment outcome. We found that the cell-membranous expression of β-catenin was stronger in HPV-positive than in HPV-negative tumors, and it was stronger in the presence of regional metastasis. The stromal vimentin expression was stronger among HPV-positive tumors. A high E-cadherin expression was associated with tumor grade. No relationship between these markers and survival emerged. In conclusion, β-catenin and vimentin seem to play different roles in OPSCC: the former in the tumor tissue itself, and the latter in the tumor stroma. HPV infection may exploit the β-catenin and vimentin pathways in carcinogenic process. More, β-catenin may serve as a marker for the occurrence of regional metastasis:

show abstract

Expression of vimentin filaments in canine malignant mammary gland tumors: A simulation of clinicopathological features of human breast cancer

Cited by 11 publications

References 16 publications

Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes

Canine mammary tumours: Size matters–a progression from low to highly malignant subtypes

Vimentin and Ki-67 immunolabeling in canine gastric carcinomas and their prognostic value

Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus–Positive and Human Papillomavirus–Negative Oropharyngeal Squamous Cell Carcinoma

Contact Info

Product

Resources

About